GPR109A (HCAR2)
Assets acting on this target.
- Class
- Niacin (vitamin B3) derivative
- Notes
- mechanism wave 2026-08-24 (PubMed co-occurrence, 2 article(s)); source: https://pubmed.ncbi.nlm.nih.gov/19080727/
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| extended-release niacin (Niaspan) | AbbVie | GPR109A (HCAR2) | Severe Hypertriglyceridemia | — | All persisted sponsor classifications for this candidate are noncommercial or government; it is retained for the clinical universe as investigator-led evidence, not as a company-directed development program. | source ↗ |